Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Completed No phase listed Observational

Events Before Death

NCT01329055
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 88 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment

NCT05411315
View directory record Official record
Conditions
Mechanical Ventilation Complication, Arterial Thrombosis, Limb Ischemia, Shock, Hypotension, Bloodstream Infection, Vasopressor Adverse Reaction, Renal Failure
Interventions
Restricted-use of arterial catheter, Standard-use of arterial catheter
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

NCT02340689
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Genetic Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Day and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 15, 2026, 9:27 AM EDT
Not listed Phase 4 Interventional

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

NCT02522650
View directory record Official record
Conditions
Proteinuria
Interventions
Amiloride, Triamterene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

NCT01129284
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Phase 1 Interventional

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

NCT06586255
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Bladder Cancer
Interventions
Concurrent Immunotherapy and Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Suspended Phase 4 Interventional Accepts healthy volunteers

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

NCT05435235
View directory record Official record
Conditions
Acute Kidney Injury, Percutaneous Coronary Intervention
Interventions
Dapagliflozin 10mg Tab
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational

Intermittent Hypoxemia and Acute Kidney Injury Study (IHAKI Study)

NCT02837276
View directory record Official record
Conditions
Intermittent Hypoxemia, Acute Kidney Injury, Preterm Infant
Interventions
Not listed
Lead sponsor
Elie G. Abu Jawdeh, MD
Other
Eligibility
Up to 2 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

NCT03015740
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration, Sitravatinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

NCT00448721
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Perifosine
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 15, 2026, 9:27 AM EDT
Withdrawn Phase 1 Interventional

A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

NCT00000685
View directory record Official record
Conditions
HIV Infections, Kidney Disease
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

NCT00001789
View directory record Official record
Conditions
Glomerulonephritis, Membranoproliferative, Lupus Nephritis
Interventions
BG9588
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy

NCT00351351
View directory record Official record
Conditions
Kidney Stones
Interventions
Cyberwand, single probe ultrasonic
Device
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351
View directory record Official record
Conditions
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational

3D Ultrasound in Women With Vacuum or Forceps Deliveries

NCT01680731
View directory record Official record
Conditions
Pelvic Floor Injury, Urinary Incontinence, Stool Incontinence
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational

Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States

NCT00340457
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 79 Years
Enrollment
2,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

A Study of ABT-751 in Patients With Renal Cell Cancer

NCT00073112
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
ABT-751
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Montebello, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

NCT01561352
View directory record Official record
Conditions
Other Haemostasis Disorder, Haemorrhagic Cystitis
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Not applicable Interventional

Inspire HER: Inspiring the Heart and Emotions for Radical Health

NCT06966258
View directory record Official record
Conditions
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases, Hypertension, Diabetes, Hyperlipidemia, Kidney Disease, Obesity, Smoking
Interventions
Inspire HER Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 79 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

NCT04534985
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Dietary
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

NCT00005831
View directory record Official record
Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 15, 2026, 9:27 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 9:27 AM EDT